NASCAR Champion Brad Keselowski to Run No. 6 NEXLIZET (bempedoic acid and ezetimibe) Ford in Famed Daytona 500CONCORD, N.C., Jan. 11, 2023 (GLOBE NEWSWIRE) -- RFK Racing has announced that Esperion Therapeutics, a Michigan-based pharmaceutical company, has partnered with the team for a multi-year ...

Based on the robustness of the CLEAR Outcomes data across primary and secondary endpoints, Company anticipates global regulatory submissions in 1H 2023 and believes it is entitled to receive milestone payments from partners upon regulatory approvals Fourth quarter 2022 U.S. net product revenue ...

ANN ARBOR, Mich., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) announced today that the Company plans to present at the J.P. Morgan 41st Annual Healthcare Conference as well as the LifeSci Partners 12th Annual Corporate Access Event. Both in-person events are taking place January 9-11th...

Demonstrates statistically significant and clinically meaningful results Bempedoic acid becomes the first ATP citrate lyase inhibitor and first oral non-statin to meet the major adverse cardiovascular events (MACE-4) primary endpoint Presentation of comprehensive data at a key medical conference in ...

Event to Include Expert-Led Discussions on State of Cardiovascular Disease Treatments and Remaining Unmet Needs Esperion Leadership Will Provide Overview of its Investigational Pipeline, Planned Scientific Focus, and Future Growth Drivers Virtual Program Begins at 10am ET Today, Wednesday, November ...